U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Structurally Diverse
Created
by admin
on Fri Dec 15 18:19:47 GMT 2023
Edited
by admin
on Fri Dec 15 18:19:47 GMT 2023
Source Materials Class ORGANISM
Source Materials Type BACTERIUM
Organism Family Clostridiaceae
Organism Genus Clostridium
Organism Species difficile
Author (HALL AND O'TOOLE, 1935) PREVOT, 1938
Part WHOLE
Record UNII
PJX89V9R6N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLOSTRIDIUM DIFFICILE
Common Name English
BACILLUS DIFFICILIS WHOLE
Common Name English
CLOSTRIDIUM DIFFICILE WHOLE
Common Name English
CLOSTRIDIUM DIFFICILE (HALL AND O'TOOLE, 1935) PREVOT, 1938
Systematic Name English
Code System Code Type Description
NCBI TAXONOMY
1496
Created by admin on Fri Dec 15 18:19:47 GMT 2023 , Edited by admin on Fri Dec 15 18:19:47 GMT 2023
PRIMARY
ITIS
960739
Created by admin on Fri Dec 15 18:19:47 GMT 2023 , Edited by admin on Fri Dec 15 18:19:47 GMT 2023
PRIMARY
RXCUI
1534764
Created by admin on Fri Dec 15 18:19:47 GMT 2023 , Edited by admin on Fri Dec 15 18:19:47 GMT 2023
PRIMARY
Catalogue of Life
WBM6
Created by admin on Fri Dec 15 18:19:47 GMT 2023 , Edited by admin on Fri Dec 15 18:19:47 GMT 2023
PRIMARY
WIKIPEDIA
Clostridium difficile
Created by admin on Fri Dec 15 18:19:47 GMT 2023 , Edited by admin on Fri Dec 15 18:19:47 GMT 2023
PRIMARY
DAILYMED
PJX89V9R6N
Created by admin on Fri Dec 15 18:19:47 GMT 2023 , Edited by admin on Fri Dec 15 18:19:47 GMT 2023
PRIMARY
FDA UNII
PJX89V9R6N
Created by admin on Fri Dec 15 18:19:47 GMT 2023 , Edited by admin on Fri Dec 15 18:19:47 GMT 2023
PRIMARY
Related Record Type Details
INHIBITOR->TARGET ORGANISM
RESULTS: REP3123 was active against a collection of 108 clinical isolates of C. difficile and against epidemic, moxifloxacin-resistant BI/NAP1/027 strains (MIC range=0.5-1 mg/L and MIC(90) = 1 mg/L). The spectrum of activity included clinically important aerobic Gram-positive cocci such as Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis and Enterococcus faecium (MIC(90)s < 1 mg/L), but REP3123 was not active against most Gram-negative bacteria. REP3123 targeted C. difficile MetRS with a calculated inhibition constant (K(i)) of 0.020 nM, and selectivity was >1000-fold over human mitochondrial and cytoplasmic MetRS. The specific mode of action within bacterial cells was demonstrated by macromolecular synthesis assays that showed inhibition of protein synthesis by REP3123, and by metS overexpression, which resulted in a 16-fold increase in MIC for REP3123. Spontaneous REP3123-resistant mutants of C. difficile (MICs, 4-128 mg/L) arose with frequencies of 10(-8)-10(-9) and harboured distinct point mutations within the metS gene, resulting in 13 different amino acid substitutions. Most of the MetRS substitutions caused reduced catalytic efficiency and a growth fitness burden.
INHIBITOR->TARGET ORGANISM
INFRASPECIFIC -> PARENT ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
C. difficile ATCC 9689
MIC
INHIBITOR->TARGET ORGANISM
The rate of recurrent C. difficile infection was significantly lower with bezlotoxumab.
Related Record Type Details
ACTIVE MOIETY